HK1244012A1 - 具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛 - Google Patents

具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛

Info

Publication number
HK1244012A1
HK1244012A1 HK18103438.4A HK18103438A HK1244012A1 HK 1244012 A1 HK1244012 A1 HK 1244012A1 HK 18103438 A HK18103438 A HK 18103438A HK 1244012 A1 HK1244012 A1 HK 1244012A1
Authority
HK
Hong Kong
Prior art keywords
derivatives
inhibitory properties
treating bone
associated pain
bone associated
Prior art date
Application number
HK18103438.4A
Other languages
English (en)
Inventor
Adrian Walmsley
Sachin Kumar Dubey
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/562,297 external-priority patent/US20150183885A1/en
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of HK1244012A1 publication Critical patent/HK1244012A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
HK18103438.4A 2014-12-05 2018-03-12 具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛 HK1244012A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/562,297 US20150183885A1 (en) 2012-06-08 2014-12-05 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP15165107 2015-04-24
PCT/EP2015/078875 WO2016087677A1 (en) 2014-12-05 2015-12-07 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain

Publications (1)

Publication Number Publication Date
HK1244012A1 true HK1244012A1 (zh) 2018-07-27

Family

ID=54838344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103438.4A HK1244012A1 (zh) 2014-12-05 2018-03-12 具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛

Country Status (7)

Country Link
EP (1) EP3227334A1 (zh)
JP (1) JP2018505853A (zh)
CN (1) CN107207599A (zh)
CA (1) CA2969940A1 (zh)
HK (1) HK1244012A1 (zh)
MA (1) MA41097A (zh)
WO (1) WO2016087677A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
JP7183268B2 (ja) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
AR114110A1 (es) * 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
EP3976657A4 (en) * 2019-05-30 2023-07-05 Sunshine Lake Pharma Co., Ltd. ANTI-TRKA ANTIBODIES AND USES THEREOF
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2023125477A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkA ANTIBODY AND APPLICATION THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
RU2433139C2 (ru) * 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
AU2009211340B2 (en) * 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
WO2012075340A2 (en) * 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
ES2666126T3 (es) * 2012-06-08 2018-05-03 Glenmark Pharmaceuticals S.A. Anticuerpos anti-TrkA humanizados con sustituciones de aminoácidos

Also Published As

Publication number Publication date
EP3227334A1 (en) 2017-10-11
CN107207599A (zh) 2017-09-26
CA2969940A1 (en) 2016-06-09
JP2018505853A (ja) 2018-03-01
MA41097A (fr) 2017-10-10
WO2016087677A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
IL258725A (en) Polypeptides with an extracellular cd80 site and their use in cancer therapy
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
EP3151797A4 (en) Methods and devices for treating the skin
IL251215B (en) Cannabinoid preparation and method for treating pain
HK1244681A1 (zh) 用於治療腫瘤形成的治療組合和方法
HK1231348A1 (zh) 調節冷凍治療的裝置和方法
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
HK1244012A1 (zh) 具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
ZA201704726B (en) Peptides and their use in the treatment of skin
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
IL252904A0 (en) Methods and factors for treating diseases
PT3406258T (pt) Medicamento para utilização no tratamento de gota
IL264600B (en) A knife for use in medical treatment
SG11201700623YA (en) Biological treatment method and biological treatment device
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
SG11201701939UA (en) Cosmetic and/or pharmaceutical composition in the form of a dispersion, method for preparing same and use thereof for skin treatment
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
IL255012A0 (en) Preparations and methods for treating skin conditions
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer